Эффективность и безопасность комбинации Lactobacillus acidophilus LA-5 и Bifidobacterium lactis ВB-12 в гастроэнтерологии, педиатрии и аллергологии | КМАХ

Эффективность и безопасность комбинации Lactobacillus acidophilus LA-5 и Bifidobacterium lactis ВB-12 в гастроэнтерологии, педиатрии и аллергологии

Клиническая Микробиология и Антимикробная Химиотерапия. 2016; 18(2):113-124

​ Андреева И.В., Стецюк О.У.
пробиотики Lactobacillus Bifidobacterium
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2016; 18(2):113-124

Аннотация

Микроорганизмы Bifidobacterium lactis BB-12 и Lactobacillus acidophilus LA-5 являются широко изученными штаммами пробиотиков. В данном обзоре представлены сведения об эффективности использования штаммов BB-12 и LA-5 и их комбинации при различных гастроэнтерологических состояниях: при лечении диареи, профилактике антибиотик-ассоциированной диареи, адъювантной терапии заболеваний, ассоциированных с Helicobacter pylori, лечении функциональных запоров и нормализации функции кишечника, а также о влиянии BB-12 и LA-5 на функционирование иммунной системы (снижение частоты инфекций дыхательных путей у детей, профилактика развития и лечение атопических заболеваний). Особое внимание уделено вопросам безопасности применения пробиотиков, в том числе у уязвимых категорий пациентов.

Андреева Ирина Вениаминовна

НИИ антимикробной химиотерапии ГБОУ ВПО СГМУ Минздрава России, Смоленск, Россия

Стецюк Ольга Ульяновна

НИИ антимикробной химиотерапии ГБОУ ВПО СГМУ Минздрава России, Смоленск, Россия

  • 1. Jungersen M., Wind A., Johansen E., et al. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12®. Microorganisms 2014; 2:92-110.
  • 2. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina. 2001:1-34.
  • 3. Saavedra J.M. Clinical applications of probiotic agents. Am J Clin Nutr 200; 73:1147S-51S.
  • 4. Reid G., Jass J., Sebulsky M.T., et al. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16:658-72.
  • 5. D’Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: metaanalysis. BMJ 2002; 324:1361.
  • 6. Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001; 73:365-73.
  • 7. Marcos A., Warnberg J., Nova E., et al. The effect of milk fermented by yogurt cultures plus Lactobacillus casei DN-114001 on the immune response of subjects under academic examination stress. Eur J Nutr 2004; 43:381-9.
  • 8. Monachese M., Burton J.P., Reid G. Bioremediation and tolerance of humans to heavy metals through microbial processes: a potential role for probiotics? Appl Environ Microbiol 2012; 78:6397-404.
  • 9. Андреева И.В., Стецюк О.У. О штаммоспецифичности пробиотиков. Клиническая Микробиология и Антимикробная Химиотерапия 2010; 12:253-4.
  • 10. van der Waaij D. Colonization resistance of the digestive tract — mechanism and clinical consequences. Nahrung 1987; 31:507-17.
  • 11. Vernazza C.L., Gibson G.R., Rastall R.A. Carbohydrate preference, acid tolerance and bile tolerance in five strains of Bifidobacterium. J Appl Microbiol 2006; 100:846-53.
  • 12. Martins F.S., Silva A.A., Vieira A.T., et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol 2009; 191:623-30.
  • 13. Collado M.C., Meriluoto J., Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 2007; 45:454-60.
  • 14. Gorbach S.L. Lactic acid bacteria and human health. Ann Med 1990; 22:37-41.
  • 15. Plockova M., Tomanova J., Chumchalova J. Inhibition of mould growth and spore production by Lactobacillus acidophilus CH5 metabolites. Bull Food Res 1997; 36:237-47.
  • 16. Tejada-Simon M.V., Lee J.H., Ustunol Z., et al. Ingestion of yogurt containing Lactobacillus acidophilus and Bifidobacterium to potentiate immunoglobulin A responses to cholera toxin in mice. J Dairy Sci 1999; 82:649-60.
  • 17. Ouwehand A.C., Salminen S., Tölkkö S., et al. Resected human colonic tissue: new model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol. 2002; 9:184-6.
  • 18. Juntunen M., Kirjavainen P.V., Ouwehand A.C., et al. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 2001; 8(2):293-6.
  • 19. Collado M.C., Jalonen L., Meriluoto J., et al. Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus. Asia Pac J Clin Nutr 2006; 15(4):570-5.
  • 20. Kekkonen R. Immunomodulatory Effects of Probiotic Bacteria In Healthy Adults. Academic Dissertation. Helsinki. 2008. 122 p.
  • 21. Pitkala K.H., Strandberg T.E., Finne Soveri U.H., et al. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007; 11:305-11.
  • 22. Uchida K., Akashi K., Kusunoki I., et al. Effect of fermented milk containing Bifidobacterium lactis BB-12® on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students. J Nutr Food 2005; 8:39-51.
  • 23. Nishida, S., Gotou, M., Akutsu, S., et al. Effect of yogurt containing Bifidobacterium lactis BB-12 on improvement of defecation and fecal microflora of healthy female adults. Milk Sci 2004; 53:71-80.
  • 24. Eskesen D., Jespersen L., Michelsen B., et al. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12(R), on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallelgroup trial. Br J Nutr 2015; 114:1638-46.
  • 25. Kainifar H., Ahanchian H., Grover Z., et al. Synbiotic in the management of infantile colic: a randomised controlled trial. J Paediatr Child Health 2014; 50:801-5.
  • 26. Saavedra J.M., Abi-Hanna A., Moore N., et al. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004; 79:261-7.
  • 27. Chouraqui J.P., Van Egroo L.D., Fichot M.C. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004; 38:288-92.
  • 28. Saavedra J.M., Bauman N.A., Oung I., et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-9.
  • 29. Chatterjee S., Kar P., Das T., Ray et al. Randomised placebocontrolled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India 2013; 61:708-12.
  • 30. Fox M.J., Ahuja K.D., Robertson I.K., et al. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open 2015; 5: e006474.
  • 31. Wenus C., Goll R., Loken E.B., et al. Prevention of antibiotic-associated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr 2008; 62:299-301.
  • 32. de Vrese M., Kristen H., Rautenberg P., et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res 2011; 78:396-403.
  • 33. Sheu B.S., Wu J.J., Lo C.Y., et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16:1669-75.
  • 34. Smith T.J., Rigassio-Radler D., Denmark R., et al. Effect of Lactobacillus rhamnosus LGG(R) and Bifidobacterium animalis ssp. lactis BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr 2013; 109:1999-2007.
  • 35. Taipale T., Pienihakkinen K., Isolauri E., et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 2011; 105:409-16.
  • 36. Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy — a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101:1722-6.
  • 37. Isolauri E. Dietary modification of atopic disease: use of probiotics in the prevention of atopic dermatitis. Curr Allergy Asthma Rep 2004; 4:270-5.
  • 38. Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003; 3:15-20.
  • 39. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109:119-21.
  • 40. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30:1604-10.
  • 41. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/ American Academy of Dermatology Association «Administrative Regulations for Evidence-Based Clinical Practice Guidelines». J Am Acad Dermatol 2004; 50:391-404.
  • 42. Прошутинская Д.В., Чикин В.В., Знаменская Л.Ф. и соавт. Федеральные клинические рекомендации по ведению больных атопическим дерматитом. Российское общество дерматовенерологов и косметологов. Москва,2015-35с.
  • 43. Lee Y.K., Salminen S. Handbook of Probiotics and Prebiotics. 2nd ed: Wiley-Interscience; 2009.
  • 44. Manson J.E., Tosteson H., Ridker P.M., et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406-16.
  • 45. Klaver F.A., van der Meer R. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol 1993; 59:1120-4.
  • 46. Pereira D.I., Gibson G.R. Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. Crit Rev Biochem Mol Biol 2002; 37:259-81.
  • 47. Tonucci L.B., Olbrich Dos Santos K.M., Licursi de Oliveira L., et al. Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Clin Nutr 2015.
  • 48. Mohamadshahi M., Veissi M., Haidari F., et al. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: A randomized controlled clinical trial. J Res Med Sci 2014; 19:531-6.
  • 49. Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A., et al. Effect of probiotic yogurt containing Lactobacillus acidophilus and Bifidobacterium lactis on lipid profile in individuals with type 2 diabetes mellitus. J Dairy Sci 2011; 94:3288-94.
  • 50. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.
  • 51. Marteau P. Safety aspects of probiotic products. Scand J Nutr 2001; 45:22-4.
  • 52. Mackay A.D., Taylor M.B., Kibbler C.C., et al. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5:290-2.
  • 53. Rautio M., Jousimies-Somer H., Kauma H., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28:1159-60.
  • 54. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38:62-9.
  • 55. Land M.H., Rouster-Stevens K., Woods C.R., et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115:178-81.
  • 56. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011; 200:1-645.
  • 57. van den Nieuwboer M., Claassen E., Morelli L., et al. Probiotic and synbiotic safety in infants under two years of age. Benef Microbes 2014; 5:45-60.
  • 58. van den Nieuwboer M., Brummer R.J., Guarner F., et al. Safety of probiotics and synbiotics in children under 18 years of age. Benef Microbes 2015; 6:615-30.
  • 59. Van den Nieuwboer M., Brummer R.J., Guarner F., et al. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes 2015; 6:3-17.
  • 60. Dugoua J.J., Machado M., Zhu X., et al. Probiotic safety in pregnancy: a systematic review and metaanalysis of randomized controlled trials of Lactobacillus, Bifidobacterium, and Saccharomyces spp. J Obstet Gynaecol Can 2009; 31:542-52.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились